Literature DB >> 20346083

Validity and reliability study for the NEI-VFO-39 scale in chronic ophthalmic diseases--Turkish version.

Emine Iyigun1, Atilla Bayer, Sevinc Tastan, Meral Demiralp, Cengizhan Acikel.   

Abstract

PURPOSE: To test the reliability and validity of National Eye Institute Visual Function Questionnaire (NEI-VFQ-39) in patients with glaucoma, cataract, diabetic retinopathy and age-related macular degeneration.
METHODS: The study was carried out on 210 patients and 51 control subjects. The data were collected by using a data collection form and NEI-VFQ-39. Statistical analyses were performed with spss for Windows version 15.0.
RESULTS: Cronbach's alpha coefficient was 0.96 for the whole group. Cronbach's alpha coefficient was between 0.97 and 0.56 for the subscales. There was a strong relationship (r > 0.80) in 12.8% with dual correlation in NEI-VFQ-39 global scales and subscales and their correlations in all participant groups. There was a statistically significant difference for the NEI-VFn global and subscale scores between the control and patient groups except for general health and ocular pain.
CONCLUSIONS: We found that the NEI-VFQ-39 was a valid and reliable scale to determine the quality of life in Turkish patients with chronic ophthalmic disease.

Entities:  

Mesh:

Year:  2010        PMID: 20346083     DOI: 10.1111/j.1755-3768.2009.01810.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  2 in total

1.  Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population.

Authors:  Elma Jelin; Torbjørn Wisløff; Morten C Moe; Turid Heiberg
Journal:  Health Qual Life Outcomes       Date:  2019-08-14       Impact factor: 3.186

2.  National Eye Institute Visual Function Scale in Type 2 Diabetes Patients.

Authors:  Sezen Akkaya; Sinay Düzova; Özlem Şahin; Haluk Kazokoğlu; Tayfun Bavbek
Journal:  J Ophthalmol       Date:  2016-02-21       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.